(99m)Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study

BACKGROUND: Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a commercially available humanized Fab′-fragment directed against TNF. A b...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:EJNMMI Res
Asıl Yazarlar: Lambert, Bieke, Carron, Philippe, D’Asseler, Yves, Bacher, Klaus, Van den Bosch, Filip, Elewaut, Dirk, Verbruggen, Gust, Beyaert, Rudi, Dumolyn, Caroline, De Vos, Filip
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2016
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5151115/
https://ncbi.nlm.nih.gov/pubmed/27957720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-016-0245-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller